小细胞肺癌化疗及免疫治疗耐药机制的研究进展<sup>★</sup>

doi:10.3969/j.issn.2095-1264.2025.02.07

首页 > 过刊浏览>2025年第15卷第2期 >197-204. DOI:10.3969/j.issn.2095-1264.2025.02.07

小细胞肺癌化疗及免疫治疗耐药机制的研究进展★
DOI:
                        10.3969/j.issn.2095-1264.2025.02.07
                    
CSTR:
                        
                    
作者:
                        
                        
                    
作者单位:1.新疆医科大学第三临床医学院，新疆 乌鲁木齐，830011;2.新疆医科大学附属肿瘤医院 肺内科， 新疆 乌鲁木齐，830011
作者简介:米克日阿依·艾合买提，女，硕士研究生，研究方向为肿瘤内科临床研究。
通讯作者:帕提古力·阿尔西丁，女，硕士，主任医师，研究方向为肿瘤内科临床研究。
中图分类号:R734.2
基金项目:★新疆维吾尔自治区自然科学基金面上项目（2022D01C294）。

Research progress on the mechanisms of chemotherapy and immunotherapy resistance in small cell lung cancer^★

Author:

Affiliation:

1.The Third Clinical Medical College of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China;2.Department of Pulmonary Medicine, the Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, 830011, Xinjiang, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

小细胞肺癌（SCLC）是一种高级别神经内分泌癌，以快速生长和转移为主要特点。初治SCLC患者对化疗高度敏感，以铂类为基础的化疗可显著提高其生存率。然而，大多数患者在化疗后容易产生耐药和复发，导致预后较差。近年来，免疫治疗通过激活或增强患者自身免疫系统来识别和攻击肿瘤细胞，为SCLC的治疗提供了新的策略，但肿瘤细胞同样可能对免疫治疗产生耐药性。因此，研究化疗及免疫治疗的耐药机制对于理解和克服耐药现象、指导临床个体化治疗依然至关重要。本文将回顾SCLC的化疗和免疫治疗及其耐药机制，并总结免疫治疗的最新研究进展，进一步探讨耐药后的治疗策略，以期为SCLC的治疗探索更好的干预措施。

Abstract:

Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma characterized by rapid growth and metastasis. Treatment-na?ve SCLC patients exhibit high sensitivity to chemotherapy, and platinum-based chemotherapy can significantly improve their survival rate. However, most patients are prone to develop drug resistance and relapse after chemotherapy, leading to their poor prognosis. In recent years, immunotherapy has emerged as a novel strategy for the treatment of SCLC by activating or enhancing the patient's own immune system to identify and attack tumor cells, yet it also faces challenges of resistance. Therefore, the study of the resistance mechanism underlying chemotherapy and immunotherapy is still crucial for understanding and overcoming drug resistance phenomenon and guiding clinical individualized treatment. This review will summarize current chemotherapy and immunotherapy approaches for SCLC, elucidate their respective resistance mechanisms, and highlight recent advances in immunotherapy, and further discuss the post-resistance treatment strategy, in order to explore better intervention measures for the treatment of SCLC.